NEWS
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Aptevo Therapeutics (NASDAQ: APVO) reports promising early results from its RAINIER trial, where the first patient treated with mipletamig achieved a 90% reduction in leukemic blasts within 30 days.
The trial evaluates mipletamig as a frontline therapy for Acute Myeloid Leukemia (AML) in combination with venetoclax and azacitidine. The triplet combination therapy targets AML through multiple mechanisms, potentially improving patient outcomes, particularly in elderly patients with treatment options.
Previous trials demonstrated favorable safety profiles with manageable cytokine release syndrome levels, along with compelling response and durability of remission.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2508Followers
107Following
27KVisitors
Follow